sign in sign up
<<
Home , Methylenedioxycathinone, Racemoramide, Tiletamine

HB2534 Engrossed LRB100 08419 RLC 18533 b

1 AN ACT concerning criminal law.

2 Be it enacted by the People of the State of Illinois,

3 represented in the General Assembly:

4 Section 5. The Illinois Controlled Substances Act is 5 amended by changing Sections 204, 206, 208, 401, and 402 as 6 follows:

7 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) 8 Sec. 204. (a) The controlled substances listed in this 9 Section are included in Schedule I. 10 (b) Unless specifically excepted or unless listed in 11 another schedule, any of the following opiates, including their 12 isomers, esters, , salts, and salts of isomers, esters, 13 and ethers, whenever the existence of such isomers, esters, 14 ethers and salts is possible within the specific chemical 15 designation: 16 (1) Acetylmethadol; 17 (1.1) Acetyl--methylfentanyl 18 (N-[1-(1-methyl-2-phenethyl)- 19 4-piperidinyl]-N-phenylacetamide); 20 (2) Allylprodine; 21 (3) Alphacetylmethadol, except 22 levo-alphacetylmethadol (also known as levo-alpha- 23 acetylmethadol, levomethadyl acetate, or LAAM); HB2534 Engrossed - 2 - LRB100 08419 RLC 18533 b

1 (4) Alphameprodine; 2 (5) Alphamethadol; 3 (6) Alpha-methylfentanyl 4 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl) 5 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N- 6 propanilido) ; 7 (6.1) Alpha-methylthiofentanyl 8 (N-[1-methyl-2-(2-thienyl)ethyl- 9 4-piperidinyl]-N-phenylpropanamide); 10 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); 11 (7.1) PEPAP 12 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); 13 (8) Benzethidine; 14 (9) Betacetylmethadol; 15 (9.1) Beta-hydroxyfentanyl 16 (N-[1-(2-hydroxy-2-phenethyl)- 17 4-piperidinyl]-N-phenylpropanamide); 18 (10) Betameprodine; 19 (11) Betamethadol; 20 (12) Betaprodine; 21 (13) Clonitazene; 22 (14) ; 23 (15) Diampromide; 24 (16) ; 25 (17) Difenoxin; 26 (18) ; HB2534 Engrossed - 3 - LRB100 08419 RLC 18533 b

1 (19) Dimepheptanol; 2 (20) Dimethylthiambutene; 3 (21) Dioxaphetylbutyrate; 4 (22) ; 5 (23) Ethylmethylthiambutene; 6 (24) Etonitazene; 7 (25) Etoxeridine; 8 (26) Furethidine; 9 (27) Hydroxpethidine; 10 (28) ; 11 (29) Levomoramide; 12 (30) Levophenacylmorphan; 13 (31) 3-Methylfentanyl 14 (N-[3-methyl-1-(2-phenylethyl)- 15 4-piperidyl]-N-phenylpropanamide); 16 (31.1) 3-Methylthiofentanyl 17 (N-[(3-methyl-1-(2-thienyl)ethyl- 18 4-piperidinyl]-N-phenylpropanamide); 19 (32) Morpheridine; 20 (33) Noracymethadol; 21 (34) Norlevorphanol; 22 (35) Normethadone; 23 (36) Norpipanone; 24 (36.1) Para-fluorofentanyl 25 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)- 26 4-piperidinyl]propanamide); HB2534 Engrossed - 4 - LRB100 08419 RLC 18533 b

1 (37) Phenadoxone; 2 (38) Phenampromide; 3 (39) Phenomorphan; 4 (40) ; 5 (41) ; 6 (42) Proheptazine; 7 (43) Properidine; 8 (44) ; 9 (45) Racemoramide; 10 (45.1) Thiofentanyl 11 (N-phenyl-N-[1-(2-thienyl)ethyl- 12 4-piperidinyl]-propanamide); 13 (46) ; 14 (47) Trimeperidine; 15 (48) Beta-hydroxy-3-methylfentanyl (other name: 16 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]- 17 N-phenylpropanamide);. 18 (49) Furanyl (FU-F); 19 (50) Butyryl fentanyl; 20 (51) Valeryl fentanyl; 21 (52) Acetyl fentanyl; 22 (53) Beta-hydroxy-thiofentanyl; 23 (54) 3,4-dichloro-N-[2- 24 (dimethylamino)cyclohexyl]-N- 25 methylbenzamide (U-47700); 26 (55) 4-chloro-N-[1-[2- HB2534 Engrossed - 5 - LRB100 08419 RLC 18533 b

1 (4-nitrophenyl)ethyl]-2-piperidinylidene]- 2 benzenesulfonamide (W-18); 3 (56) 4-chloro-N-[1-(2-phenylethyl) 4 -2-piperidinylidene]-benzenesulfonamide (W-15); 5 (57) (acryloylfentanyl). 6 (c) Unless specifically excepted or unless listed in 7 another schedule, any of the following derivatives, its 8 salts, isomers and salts of isomers, whenever the existence of 9 such salts, isomers and salts of isomers is possible within the 10 specific chemical designation: 11 (1) Acetorphine; 12 (2) ; 13 (3) ; 14 (4) methylbromide; 15 (5) Codeine-N-Oxide; 16 (6) ; 17 (7) ; 18 (8) Diacetyldihydromorphine (Dihydroheroin); 19 (9) ; 20 (10) Drotebanol; 21 (11) (except hydrochloride salt); 22 (12) ; 23 (13) ; 24 (14) Methyldesorphine; 25 (15) Methyldihydromorphine; 26 (16) methylbromide; HB2534 Engrossed - 6 - LRB100 08419 RLC 18533 b

1 (17) Morphine methylsulfonate; 2 (18) Morphine-N-Oxide; 3 (19) Myrophine; 4 (20) ; 5 (21) ; 6 (22) Normorphine; 7 (23) Pholcodine; 8 (24) Thebacon. 9 (d) Unless specifically excepted or unless listed in 10 another schedule, any material, compound, mixture, or 11 preparation which contains any quantity of the following 12 hallucinogenic substances, or which contains any of its salts, 13 isomers and salts of isomers, whenever the existence of such 14 salts, isomers, and salts of isomers is possible within the 15 specific chemical designation (for the purposes of this 16 paragraph only, the term "isomer" includes the optical, 17 position and geometric isomers): 18 (1) 3,4-methylenedioxyamphetamine 19 (alpha-methyl,3,4-methylenedioxyphenethylamine, 20 methylenedioxyamphetamine, MDA); 21 (1.1) Alpha-ethyltryptamine 22 (some trade or other names: etryptamine; 23 MONASE; alpha-ethyl-1H-indole-3-ethanamine; 24 3-(2-aminobutyl)indole; a-ET; and AET); 25 (2) 3,4-methylenedioxymethamphetamine (MDMA); 26 (2.1) 3,4-methylenedioxy-N-ethylamphetamine HB2534 Engrossed - 7 - LRB100 08419 RLC 18533 b

1 (also known as: N-ethyl-alpha-methyl- 2 3,4(methylenedioxy) , N-ethyl MDA, MDE, 3 and MDEA); 4 (2.2) N- (BZP); 5 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); 6 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); 7 (4) 3,4,5- (TMA); 8 (5) (Blank); 9 (6) (DET); 10 (7) Dimethyltryptamine (DMT); 11 (7.1) 5-Methoxy-diallyltryptamine; 12 (8) 4-methyl-2,5- (DOM, STP); 13 (9) (some trade and other names: 14 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy- 15 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b] 16 indole; Tabernanthe iboga); 17 (10) Lysergic acid diethylamide; 18 (10.1) ; 19 (10.5) (meaning all parts of the plant 20 presently classified botanically as Salvia divinorum, 21 whether growing or not, the seeds thereof, any extract from 22 any part of that plant, and every compound, manufacture, 23 salts, isomers, and salts of isomers whenever the existence 24 of such salts, isomers, and salts of isomers is possible 25 within the specific chemical designation, derivative, 26 mixture, or preparation of that plant, its seeds or HB2534 Engrossed - 8 - LRB100 08419 RLC 18533 b

1 extracts); 2 (11) 3,4,5-trimethoxyphenethylamine (); 3 (12) Peyote (meaning all parts of the plant presently 4 classified botanically as Lophophora williamsii Lemaire, 5 whether growing or not, the seeds thereof, any extract from 6 any part of that plant, and every compound, manufacture, 7 salts, derivative, mixture, or preparation of that plant, 8 its seeds or extracts); 9 (13) N-ethyl-3-piperidyl benzilate (JB 318); 10 (14) N-methyl-3-piperidyl benzilate; 11 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine 12 (also known as N-hydroxy-alpha-methyl- 13 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); 14 (15) ; some trade or other names: 15 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- 16 dibenzo (b,d) pyran; Synhexyl; 17 (16) ; 18 (17) Psilocyn; 19 (18) Alpha-methyltryptamine (AMT); 20 (19) 2,5-dimethoxyamphetamine 21 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); 22 (20) 4-bromo-2,5-dimethoxyamphetamine 23 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; 24 4-bromo-2,5-DMA); 25 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine. 26 Some trade or other names: 2-(4-bromo- HB2534 Engrossed - 9 - LRB100 08419 RLC 18533 b

1 2,5-dimethoxyphenyl)-1-aminoethane; 2 alpha-desmethyl DOB, 2CB, Nexus; 3 (21) 4-methoxyamphetamine 4 (4-methoxy-alpha-methylphenethylamine; 5 paramethoxyamphetamine; PMA); 6 (22) (Blank); 7 (23) Ethylamine analog of . 8 Some trade or other names: 9 N-ethyl-1-phenylcyclohexylamine, 10 (1-phenylcyclohexyl) ethylamine, 11 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; 12 (24) analog of phencyclidine. Some trade 13 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy, 14 PHP; 15 (25) 5-methoxy-3,4-methylenedioxy-; 16 (26) 2,5-dimethoxy-4-ethylamphetamine 17 (another name: DOET); 18 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine 19 (another name: TCPy); 20 (28) (Blank); 21 (29) Thiophene analog of phencyclidine (some trade 22 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine; 23 2-thienyl analog of phencyclidine; TPCP; TCP); 24 (29.1) Benzothiophene analog of phencyclidine Some 25 trade or other names: BTCP or ; 26 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); HB2534 Engrossed - 10 - LRB100 08419 RLC 18533 b

1 (30) Bufotenine (some trade or other names: 2 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole; 3 3-(2-dimethylaminoethyl)-5-indolol; 4 5-hydroxy-N,N-dimethyltryptamine; 5 N,N-dimethylserotonin; mappine); 6 (31) (Blank); 1-Pentyl-3-(1-naphthoyl)indole 7 Some trade or other names: JWH-018; 8 (32) (Blank); 1-Butyl-3-(1-naphthoyl)indole 9 Some trade or other names: JWH-073; 10 (33) (Blank); 1-[(5-fluoropentyl)-1H-indol-3-yl]- 11 (2-iodophenyl)methanone 12 Some trade or other names: AM-694; 13 (34) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5- 14 (2-methyloctan-2-yl)phenol 15 Some trade or other names: CP 47,497 16 and its C6, C8 and C9 homologs; 17 (34.5) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5- 18 (2-methyloctan-2-yl)phenol), where side chain n=5; 19 and homologues where side chain n=4, 6, or 7; Some 20 trade or other names: CP 47,497; 21 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- 22 (2-methyloctan-2-yl)-6a,7, 23 10,10a-tetrahydrobenzo[c]chromen-1-ol 24 Some trade or other names: HU-210; 25 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- 26 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- HB2534 Engrossed - 11 - LRB100 08419 RLC 18533 b

1 tetrahydrobenzo[c]chromen-1-ol, its isomers, 2 salts, and salts of isomers; Some trade or other 3 names: HU-210, ; 4 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- 5 6,6-dimethyl-3-(2-methyloctan-2-yl)- 6 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol 7 Some trade or other names: HU-211; 8 (37) (Blank); (2-methyl-1-propyl-1H-indol- 9 3-yl)-1-naphthalenyl-methanone 10 Some trade or other names: JWH-015; 11 (38) (Blank); 4-methoxynaphthalen-1-yl- 12 (1-pentylindol-3-yl)methanone 13 Some trade or other names: JWH-081; 14 (39) (Blank); 1-Pentyl-3-(4-methyl-1-naphthoyl)indole 15 Some trade or other names: JWH-122; 16 (40) (Blank); 2-(2-methylphenyl)-1-(1-pentyl- 17 1H-indol-3-yl)-ethanone 18 Some trade or other names: JWH-251; 19 (41) (Blank); 1-(2-cyclohexylethyl)-3- 20 (2-methoxyphenylacetyl)indole 21 Some trade or other names: RCS-8, BTW-8 and SR-18; 22 (42) Any compound structurally derived from 23 3-(1-naphthoyl)indole or 1H-indol-3-yl- 24 (1-naphthyl)methane by substitution at the 25 nitrogen atom of the indole ring by alkyl, haloalkyl, 26 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, HB2534 Engrossed - 12 - LRB100 08419 RLC 18533 b

1 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 2 or 2-(4-morpholinyl)ethyl whether or not further 3 substituted in the indole ring to any extent, whether 4 or not substituted in the naphthyl ring to any extent. 5 Examples of this structural class include, but are 6 not limited to, JWH-018, AM-2201, JWH-175, JWH-184, 7 and JWH-185; 8 (43) Any compound structurally derived from 9 3-(1-naphthoyl)pyrrole by substitution at the nitrogen 10 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, 11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 12 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 13 or 2-(4-morpholinyl)ethyl, whether or not further 14 substituted in the pyrrole ring to any extent, whether 15 or not substituted in the naphthyl ring to any extent. 16 Examples of this structural class include, but are not 17 limited to, JWH-030, JWH-145, JWH-146, JWH-307, and 18 JWH-368; 19 (44) Any compound structurally derived from 20 1-(1-naphthylmethyl)indene by substitution 21 at the 3-position of the indene ring by alkyl, haloalkyl, 22 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 23 halide, alkyl aryl halide, 1-(N-methyl- 24 2-piperidinyl)methyl, or 2-(4- 25 morpholinyl)ethyl whether or not further substituted in 26 the indene ring to any extent, whether or not substituted HB2534 Engrossed - 13 - LRB100 08419 RLC 18533 b

1 in the naphthyl ring to any extent. Examples of 2 this structural class include, but are not 3 limited to, JWH-176; 4 (45) Any compound structurally derived from 5 3-phenylacetylindole by substitution at the 6 nitrogen atom of the indole ring with alkyl, haloalkyl, 7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 8 halide, alkyl aryl halide, 1-(N-methyl-2- 9 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 10 whether or not further substituted in the indole ring 11 to any extent, whether or not substituted in the phenyl 12 ring to any extent. Examples of this structural 13 class include, but are not limited to, JWH-167, 14 JWH-250, JWH-251, and RCS-8; 15 (46) Any compound structurally derived from 16 2-(3-hydroxycyclohexyl)phenol by substitution 17 at the 5-position of the phenolic ring by alkyl, 18 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 19 aryl halide, alkyl aryl halide, 1-(N-methyl-2- 20 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 21 whether or not substituted in the cyclohexyl ring to any 22 extent. Examples of this structural class 23 include, but are not limited to, CP 47, 24 497 and its C8 homologue (cannabicyclohexanol); 25 (46.1) Any compound structurally 26 derived from Benzoylindoles: Any compound HB2534 Engrossed - 14 - LRB100 08419 RLC 18533 b

1 containing a 3-(benzoyl) indole structure with 2 substitution at the nitrogen atom of the 3 indole ring by an alkyl, haloalkyl, alkenyl, 4 cycloalkylmethyl, cycloalkylethyl, 5 aryl halide, alkyl aryl halide, 6 1-(N-methyl-2-piperidinyl)methyl, 7 or 2-(4-morpholinyl)ethyl group 8 whether or not further substituted 9 in the indole ring to any extent and 10 whether or not substituted in the phenyl ring 11 to any extent. Examples of this structural class 12 include, but are not limited, to, AM-630, 13 AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; 14 (47) (Blank); 3,4-Methylenedioxymethcathinone 15 Some trade or other names: ; 16 (48) (Blank); 3,4-Methyenedioxypyrovalerone 17 Some trade or other names: MDPV; 18 (49) (Blank); 4-Methylmethcathinone 19 Some trade or other names: ; 20 (50) (Blank); 4-methoxymethcathinone; 21 (51) (Blank); 4-Fluoromethcathinone; 22 (52) (Blank); 3-Fluoromethcathinone; 23 (53) 2,5-Dimethoxy-4-(n)-propylthio- 24 phenethylamine; 25 Some trade or other names: -T-7; 26 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine HB2534 Engrossed - 15 - LRB100 08419 RLC 18533 b

1 Some trade or other names: 2C-E; 2 (53.2) 2,5-dimethoxy-4-methylphenethylamine 3 Some trade or other names: 2C-D; 4 (53.3) 4-chloro-2,5-dimethoxyphenethylamine 5 Some trade or other names: 2C-C; 6 (53.4) 4-iodo-2,5-dimethoxyphenethylamine 7 Some trade or other names: 2C-I; 8 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine 9 Some trade or other names: 2C-T-2; 10 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine 11 Some trade or other names: 2C-T-4; 12 (53.7) 2,5-dimethoxyphenethylamine 13 Some trade or other names: 2C-H; 14 (53.8) 2,5-dimethoxy-4-nitrophenethylamine 15 Some trade or other names: 2C-N; 16 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine 17 Some trade or other names: 2C-P; 18 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine 19 Some trade or other names: 2C-G; 20 (53.11) The N-(2-methoxybenzyl) derivative of any 2C 21 phenethylamine referred to in subparagraphs (20.1), (53), 22 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), 23 (53.8), (53.9), and (53.10) including, but not limited to, 24 25I-NBOMe and 25C-NBOMe; 25 (54) 5-Methoxy-N,N-; 26 (55) (Blank); ; HB2534 Engrossed - 16 - LRB100 08419 RLC 18533 b

1 (56) (Blank); 4-iodo-2,5-dimethoxy-N-((2-methoxy 2 phenyl)methyl)-benzeneethanamine 3 (trade or other name: 25I-NBOMe); 4 (57) (Blank); 4-chloro-2,5-dimethoxy- 5 N-[(2-methoxyphenyl) methyl]-benzeneethanamine 6 (trade or other name: 25C-NBOMe); 7 (58) (Blank); 4-bromo-2,5-dimethoxy 8 -N-[(2-methoxyphenyl) methyl]-benzeneethanamine 9 (trade or other name: 25B-NBOMe); 10 (59) 3-cyclopropoylindole with 11 substitution at the nitrogen atom of the 12 indole ring by alkyl, haloalkyl, alkenyl, 13 cycloalkylmethyl, cycloalkylethyl, aryl 14 halide, alkyl aryl halide, 15 1-(N-methyl-2-piperidinyl)methyl, or 16 2-(4-morpholinyl)ethyl, whether or not 17 further substituted on the indole ring 18 to any extent, whether or not substituted 19 on the cyclopropyl ring to any extent: 20 including, but not limited to, XLR11, 21 UR144, FUB-144; 22 (60) 3-adamantoylindole with 23 substitution at the nitrogen atom of the 24 indole ring by alkyl, haloalkyl, alkenyl, 25 cycloalkylmethyl, cycloalkylethyl, 26 aryl halide, alkyl aryl halide, HB2534 Engrossed - 17 - LRB100 08419 RLC 18533 b

1 1-(N-methyl-2-piperidinyl)methyl, or 2 2-(4-morpholinyl)ethyl, whether or not 3 further substituted on the indole ring to 4 any extent, whether or not substituted on 5 the adamantyl ring to any extent: including, 6 but not limited to, AB-001; 7 (61) N-(adamantyl)-indole-3-carboxamide 8 with substitution at the nitrogen atom of the 9 indole ring by alkyl, haloalkyl, alkenyl, 10 cycloalkylmethyl, cycloalkylethyl, aryl halide, 11 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 12 or 2-(4-morpholinyl)ethyl, whether or not further 13 substituted on the indole ring to any extent, whether 14 or not substituted on the adamantyl ring to any 15 extent: including, but not limited to, 16 APICA/2NE-1, STS-135; 17 (62) N-(adamantyl)-indazole-3-carboxamide 18 with substitution at a nitrogen atom of the indazole 19 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 20 cycloalkylethyl, aryl halide, alkyl aryl halide, 21 1-(N-methyl-2-piperidinyl)methyl, or 22 2-(4-morpholinyl)ethyl, whether or not further 23 substituted on the indazole ring to any extent, 24 whether or not substituted on the adamantyl 25 ring to any extent: including, but not limited 26 to, AKB48, 5F-AKB48; HB2534 Engrossed - 18 - LRB100 08419 RLC 18533 b

1 (63) 1H-indole-3-carboxylic acid 8-quinolinyl 2 ester with substitution at the nitrogen atom of the 3 indole ring by alkyl, haloalkyl, alkenyl, 4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 5 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 6 2-(4-morpholinyl)ethyl, whether or not further 7 substituted on the indole ring to any extent, 8 whether or not substituted on the quinoline ring 9 to any extent: including, but not limited to, PB22, 10 5F-PB22, FUB-PB-22; 11 (64) 3-(1-naphthoyl)indazole with 12 substitution at the nitrogen atom of the 13 indazole ring by alkyl, haloalkyl, 14 alkenyl, cycloalkylmethyl, cycloalkylethyl, 15 aryl halide, alkyl aryl halide, 16 1-(N-methyl-2-piperidinyl)methyl, or 17 2-(4-morpholinyl)ethyl, whether or not further 18 substituted on the indazole ring to any extent, 19 whether or not substituted on the naphthyl ring 20 to any extent: including, but not limited to, 21 THJ-018, THJ-2201; 22 (65) 2-(1-naphthoyl)benzimidazole with 23 substitution at the nitrogen atom of the benzimidazole 24 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 25 cycloalkylethyl, aryl halide, alkyl aryl halide, 26 1-(N-methyl-2-piperidinyl)methyl, or HB2534 Engrossed - 19 - LRB100 08419 RLC 18533 b

1 2-(4-morpholinyl)ethyl, whether or not further 2 substituted on the benzimidazole ring to any extent, 3 whether or not substituted on the naphthyl ring to 4 any extent: including, but not limited to, FUBIMINA; 5 (66) N-(1-amino-3-methyl-1-oxobutan-2-yl) 6 -1H-indazole-3-carboxamide with substitution on the 7 nitrogen atom of the indazole ring by alkyl, 8 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 9 aryl halide, alkyl aryl halide, 1-(N-methyl-2- 10 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 11 whether or not further substituted on the indazole 12 ring to any extent: including, but not limited to, 13 AB-PINACA, AB-FUBINACA, AB-CHMINACA; 14 (67) N-(1-amino-3,3-dimethyl-1-oxobutan- 15 2-yl)-1H-indazole-3-carboxamide with substitution 16 on the nitrogen atom of the indazole ring by alkyl, 17 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 18 aryl halide, alkyl aryl halide, 1-(N-methyl-2- 19 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether 20 or not further substituted on the indazole ring to any 21 extent: including, but not limited to, ADB-PINACA, 22 ADB-FUBINACA; 23 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- 24 1H-indole-3-carboxamide with substitution on the nitrogen 25 atom of the indole ring by alkyl, haloalkyl, alkenyl, 26 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl HB2534 Engrossed - 20 - LRB100 08419 RLC 18533 b

1 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2 2-(4-morpholinyl)ethyl, whether or not further 3 substituted on the indole ring to any extent: 4 including, but not limited to, ADBICA, 5F-ADBICA; 5 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)- 6 1H-indole-3-carboxamide with substitution on the 7 nitrogen atom of the indole ring by alkyl, haloalkyl, 8 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 9 halide, alkyl aryl halide, 1-(N-methyl-2- 10 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 11 whether or not further substituted on the indole 12 ring to any extent: including, but not limited 13 to, ABICA, 5F-ABICA; 14 (70) Methyl 2-(1H-indazole-3-carboxamido)- 15 3-methylbutanoate with substitution on the nitrogen 16 atom of the indazole ring by alkyl, haloalkyl, 17 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 18 halide, alkyl aryl halide, 1-(N-methyl-2- 19 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 20 whether or not further substituted on the indazole 21 ring to any extent: including, but not limited to, AMB, 22 5F-AMB. 23 (71) Methyl 2-(1H-indazole-3-carboxamido) 24 -3,3-dimethylbutanoate with substitution on the nitrogen 25 atom of the indazole ring by alkyl, haloalkyl, alkenyl, 26 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl HB2534 Engrossed - 21 - LRB100 08419 RLC 18533 b

1 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2- 2 (4-morpholinyl)ethyl, whether or not further substituted 3 on the indazole ring to any extent: including, but not 4 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; 5 (72) Methyl 2-(1H-indole-3-carboxamido)- 6 3-methylbutanoate with substitution on the nitrogen atom 7 of the indole ring by alkyl, haloalkyl, alkenyl, 8 cycloalkylmethyl, cycloalkylethyl, aryl halide, 9 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 10 or 2-(4-morpholinyl)ethyl, whether or not further 11 substituted on the indazole ring to any extent: 12 including, but not limited to, MMB018, MMB2201, 13 and AMB-CHMICA; 14 (73) Methyl 2-(1H-indole-3- 15 carboxamido)-3,3-dimethylbutanoate with substitution 16 on the nitrogen atom of the indole ring by alkyl, 17 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 18 aryl halide, alkyl aryl halide, 1-(N-methyl-2- 19 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 20 whether or not further substituted on the 21 indazole ring to any extent: including, but 22 not limited to, MDMB-CHMICA; 23 (74) N-(1-Amino-1-oxo-3-phenylpropan 24 -2-yl) -1H-indazole-3-carboxamide with 25 substitution on the nitrogen atom of the indazole 26 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, HB2534 Engrossed - 22 - LRB100 08419 RLC 18533 b

1 cycloalkylethyl, aryl halide, alkyl aryl halide, 2 1-(N-methyl-2-piperidinyl)methyl, or 2-(4- 3 morpholinyl)ethyl, whether or not further 4 substituted on the indazole ring to any 5 extent: including, but not limited to, APP-CHMINACA, 6 5-fluoro-APP-PINACA; 7 (75) N-(1-Amino-1-oxo-3-phenylpropan 8 -2-yl)-1H-indole-3-carboxamide with substitution on 9 the nitrogen atom of the indole ring by alkyl, 10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 11 aryl halide, alkyl aryl halide, 1-(N-methyl-2- 12 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 13 whether or not further substituted on the indazole 14 ring to any extent: including, but not limited to, 15 APP-PICA and 5-fluoro-APP-PICA; 16 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name 17 4-AcO-DMT; 18 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: Trade 19 name 5-MeO-MIPT; 20 (78) 4-hydroxy Diethyltryptamine (4-HO-DET); 21 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); 22 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); 23 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine 24 (4-HO-MiPT); 25 (82) Fluorophenylpiperazine; 26 (83) ; HB2534 Engrossed - 23 - LRB100 08419 RLC 18533 b

1 (84) 1-(Ethylamino)-2-phenylpropan-2- 2 one (iso-). 3 (e) Unless specifically excepted or unless listed in 4 another schedule, any material, compound, mixture, or 5 preparation which contains any quantity of the following 6 substances having a depressant effect on the central nervous 7 system, including its salts, isomers, and salts of isomers 8 whenever the existence of such salts, isomers, and salts of 9 isomers is possible within the specific chemical designation: 10 (1) mecloqualone; 11 (2) methaqualone; and 12 (3) gamma hydroxybutyric acid. 13 (f) Unless specifically excepted or unless listed in 14 another schedule, any material, compound, mixture, or 15 preparation which contains any quantity of the following 16 substances having a effect on the central nervous 17 system, including its salts, isomers, and salts of isomers: 18 (1) ; 19 (2) N-ethylamphetamine; 20 (3) (some other names: 21 2-amino-5-phenyl-2-; aminoxaphen; 22 4-5-dihydro-5-phenyl-2-oxazolamine) and its 23 salts, optical isomers, and salts of optical isomers; 24 (4) (some other names: 25 2-methylamino-1-phenylpropan-1-one; 26 Ephedrone; 2-(methylamino)-propiophenone; HB2534 Engrossed - 24 - LRB100 08419 RLC 18533 b

1 alpha-(methylamino)propiophenone; N-methylcathinone; 2 methycathinone; Monomethylpropion; UR 1431) and its 3 salts, optical isomers, and salts of optical isomers; 4 (5) (some trade or other names: 5 2-aminopropiophenone; alpha-aminopropiophenone; 6 2-amino-1-phenyl-propanone; norephedrone); 7 (6) N,N- (also known as: 8 N,N-alpha-trimethyl-benzeneethanamine; 9 N,N-alpha-trimethylphenethylamine); 10 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis- 11 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); 12 (8) 3,4-Methylenedioxypyrovalerone (MDPV);. 13 (9) Halogenated and 14 – any compound derived from either 15 amphetamine or through the substitution 16 of a halogen on the phenyl ring, including, but not 17 limited to, 2-fluoroamphetamine, 3- 18 fluoroamphetamine and 4-fluoroamphetamine; 19 (10) Aminopropylbenzofuran (APB): 20 including 4-(2-Aminopropyl) benzofuran, 5- 21 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl) 22 benzofuran, and 7-(2-Aminopropyl) benzofuran; 23 (11) Aminopropyldihydrobenzofuran (APDB): 24 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran, 25 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran, 26 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, HB2534 Engrossed - 25 - LRB100 08419 RLC 18533 b

1 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 2 (12) Methylaminopropylbenzofuran 3 (MAPB): including 4-(2-methylaminopropyl) 4 benzofuran, 5-(2-methylaminopropyl)benzofuran, 5 6-(2-methylaminopropyl)benzofuran 6 and 7-(2-methylaminopropyl)benzofuran. 7 (g) Temporary listing of substances subject to emergency 8 scheduling. Any material, compound, mixture, or preparation 9 that contains any quantity of the following substances: 10 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide 11 (benzylfentanyl), its optical isomers, isomers, salts, 12 and salts of isomers; 13 (2) N-[1(2-thienyl) 14 methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), 15 its optical isomers, salts, and salts of isomers. 16 (h) Synthetic . Unless specifically excepted, 17 any chemical compound which is not approved by the United 18 States Food and Drug Administration or, if approved, is not 19 dispensed or possessed in accordance with State or federal law, 20 not including , structurally derived from 21 2-aminopropan-1-one by substitution at the 1-position with 22 either phenyl, naphthyl, or thiophene ring systems, whether or 23 not the compound is further modified in one or more of the 24 following ways: 25 (1) by substitution in the ring system to 26 any extent with alkyl, alkylenedioxy, alkoxy, HB2534 Engrossed - 26 - LRB100 08419 RLC 18533 b

1 haloalkyl, hydroxyl, or halide substituents, whether 2 or not further substituted in the ring system 3 by one or more other univalent substituents. 4 Examples of this class include, but are not 5 limited to, 3,4- 6 (bk-MDA); 7 (2) by substitution at the 3-position 8 with an acyclic alkyl substituent. Examples of 9 this class include, but are not limited to, 10 2-methylamino-1-phenylbutan-1-one 11 (); or 12 (3) by substitution at the 2-amino nitrogen 13 atom with alkyl, dialkyl, benzyl, or methoxybenzyl 14 groups, or by inclusion of the 2-amino nitrogen atom 15 in a cyclic structure. Examples of this class include, 16 but are not limited to, Dimethylcathinone, Ethcathinone, 17 and a-Pyrrolidinopropiophenone (a-PPP). 18 (Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised 19 10-25-16.)

20 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206) 21 Sec. 206. (a) The controlled substances listed in this 22 Section are included in Schedule II. 23 (b) Unless specifically excepted or unless listed in 24 another schedule, any of the following substances whether 25 produced directly or indirectly by extraction from substances HB2534 Engrossed - 27 - LRB100 08419 RLC 18533 b

1 of vegetable origin, or independently by means of chemical 2 synthesis, or by combination of extraction and chemical 3 synthesis: 4 (1) Opium and opiates, and any salt, compound, 5 derivative or preparation of opium or opiate, excluding 6 , , levopropoxyphene, , 7 , , and , and their respective 8 salts, but including the following: 9 (i) Raw Opium; 10 (ii) Opium extracts; 11 (iii) Opium fluid extracts; 12 (iv) Powdered opium; 13 (v) Granulated opium; 14 (vi) Tincture of opium; 15 (vii) Codeine; 16 (viii) ; 17 (ix) Etorphine Hydrochloride; 18 (x) ; 19 (xi) ; 20 (xii) ; 21 (xiii) Morphine; 22 (xiii.5) 6-Monoacetylmorphine; 23 (xiv) ; 24 (xv) ; 25 (xv.5) ; 26 (xvi) ; HB2534 Engrossed - 28 - LRB100 08419 RLC 18533 b

1 (xvii) Thebaine-derived . 2 (xviii) , except drug 3 products containing dextromethorphan that may be 4 dispensed pursuant to a prescription order of a 5 practitioner and are sold in compliance with the safety 6 and labeling standards as set forth by the United 7 States Food and Drug Administration, or drug products 8 containing dextromethorphan that are sold in solid, 9 tablet, liquid, capsule, powder, thin film, or gel form 10 and which are formulated, packaged, and sold in dosages 11 and concentrations for use as an over-the-counter drug 12 product. For the purposes of this Section, 13 "over-the-counter drug product" means a drug that is 14 available to consumers without a prescription and sold 15 in compliance with the safety and labeling standards as 16 set forth by the United States Food and Drug 17 Administration. 18 (2) Any salt, compound, isomer, derivative or 19 preparation thereof which is chemically equivalent or 20 identical with any of the substances referred to in 21 subparagraph (1), but not including the isoquinoline 22 alkaloids of opium; 23 (3) Opium poppy and poppy straw; 24 (4) leaves and any salt, compound, isomer, salt of 25 an isomer, derivative, or preparation of coca leaves 26 including or ecgonine, and any salt, compound, HB2534 Engrossed - 29 - LRB100 08419 RLC 18533 b

1 isomer, derivative, or preparation thereof which is 2 chemically equivalent or identical with any of these 3 substances, but not including decocainized coca leaves or 4 extractions of coca leaves which do not contain cocaine or 5 ecgonine (for the purpose of this paragraph, the term 6 "isomer" includes optical, positional and geometric 7 isomers); 8 (5) Concentrate of poppy straw (the crude extract of 9 poppy straw in either liquid, solid or powder form which 10 contains the phenanthrine alkaloids of the opium poppy). 11 (c) Unless specifically excepted or unless listed in 12 another schedule any of the following opiates, including their 13 isomers, esters, ethers, salts, and salts of isomers, whenever 14 the existence of these isomers, esters, ethers and salts is 15 possible within the specific chemical designation, dextrorphan 16 excepted: 17 (1) ; 18 (1.1) ; 19 (1.2) Thiafentanyl; 20 (2) Alphaprodine; 21 (3) ; 22 (4) ; 23 (5) Bulk (non-dosage forms); 24 (6) ; 25 (7) ; 26 (8) Fentanyl; HB2534 Engrossed - 30 - LRB100 08419 RLC 18533 b

1 (9) ; 2 (9.5) ; 3 (10) ; 4 (11) (Blank); ; 5 (12) (Levorphan); 6 (13) ; 7 (14) ; 8 (15) Methadone-Intermediate, 9 4-cyano-2-dimethylamino-4,4-diphenyl-1-; 10 (16) Moramide-Intermediate, 11 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic 12 acid; 13 (17) (meperidine); 14 (18) Pethidine-Intermediate-A, 15 4-cyano-1-methyl-4-phenylpiperidine; 16 (19) Pethidine-Intermediate-B, 17 ethyl-4-phenylpiperidine-4-carboxylate; 18 (20) Pethidine-Intermediate-C, 19 1-methyl-4-phenylpiperidine-4-carboxylic acid; 20 (21) ; 21 (22) ; 22 (23) Racemethorphan; 23 (24) (Blank); ; 24 (25) Levo-alphacetylmethadol (some other names: 25 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM). 26 (d) Unless specifically excepted or unless listed in HB2534 Engrossed - 31 - LRB100 08419 RLC 18533 b

1 another schedule, any material, compound, mixture, or 2 preparation which contains any quantity of the following 3 substances having a stimulant effect on the central nervous 4 system: 5 (1) Amphetamine, its salts, optical isomers, and salts 6 of its optical isomers; 7 (2) Methamphetamine, its salts, isomers, and salts of 8 its isomers; 9 (3) and its salts; 10 (4) ; 11 (5) . 12 (e) Unless specifically excepted or unless listed in 13 another schedule, any material, compound, mixture, or 14 preparation which contains any quantity of the following 15 substances having a depressant effect on the central nervous 16 system, including its salts, isomers, and salts of isomers 17 whenever the existence of such salts, isomers, and salts of 18 isomers is possible within the specific chemical designation: 19 (1) Amobarbital; 20 (2) Secobarbital; 21 (3) ; 22 (4) ; 23 (5) Phencyclidine; 24 (6) Gluthethimide; 25 (7) (Blank). 26 (f) Unless specifically excepted or unless listed in HB2534 Engrossed - 32 - LRB100 08419 RLC 18533 b

1 another schedule, any material, compound, mixture, or 2 preparation which contains any quantity of the following 3 substances: 4 (1) Immediate precursor to amphetamine and 5 methamphetamine: 6 (i) Phenylacetone 7 Some trade or other names: phenyl-2-propanone; 8 P2P; benzyl methyl ketone; methyl benzyl ketone. 9 (2) Immediate precursors to phencyclidine: 10 (i) 1-phenylcyclohexylamine; 11 (ii) 1-piperidinocyclohexanecarbonitrile (PCC). 12 (3) . 13 (Source: P.A. 97-334, eff. 1-1-12.)

14 (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208) 15 Sec. 208. (a) The controlled substances listed in this 16 Section are included in Schedule III. 17 (b) Unless specifically excepted or unless listed in 18 another schedule, any material, compound, mixture, or 19 preparation which contains any quantity of the following 20 substances having a stimulant effect on the central nervous 21 system, including its salts, isomers (whether optical 22 position, or geometric), and salts of such isomers whenever the 23 existence of such salts, isomers, and salts of isomers is 24 possible within the specific chemical designation; 25 (1) Those compounds, mixtures, or preparations in HB2534 Engrossed - 33 - LRB100 08419 RLC 18533 b

1 dosage unit form containing any stimulant substances 2 listed in Schedule II which compounds, mixtures, or 3 preparations were listed on August 25, 1971, as excepted 4 compounds under Title 21, Code of Federal Regulations, 5 Section 308.32, and any other drug of the quantitative 6 composition shown in that list for those drugs or which is 7 the same except that it contains a lesser quantity of 8 controlled substances; 9 (2) ; 10 (3) ; 11 (4) ; 12 (5) . 13 (c) Unless specifically excepted or unless listed in 14 another schedule, any material, compound, mixture, or 15 preparation which contains any quantity of the following 16 substances having a potential for abuse associated with a 17 depressant effect on the central nervous system: 18 (1) Any compound, mixture, or preparation containing 19 amobarbital, secobarbital, pentobarbital or any salt 20 thereof and one or more other active medicinal ingredients 21 which are not listed in any schedule; 22 (2) Any suppository dosage form containing 23 amobarbital, secobarbital, pentobarbital or any salt of 24 any of these drugs and approved by the Federal Food and 25 Drug Administration for marketing only as a suppository; 26 (3) Any substance which contains any quantity of a HB2534 Engrossed - 34 - LRB100 08419 RLC 18533 b

1 derivative of barbituric acid, or any salt thereof: 2 (3.1) Aprobarbital; 3 (3.2) Butabarbital (secbutabarbital); 4 (3.3) Butalbital; 5 (3.4) Butobarbital (butethal); 6 (4) Chlorhexadol; 7 (5) Methyprylon; 8 (6) Sulfondiethylmethane; 9 (7) Sulfonethylmethane; 10 (8) ; 11 (9) Lysergic acid; 12 (10) Lysergic acid amide; 13 (10.1) or or both, or any salt of 14 either of them. 15 Some trade or other names for a tiletamine-zolazepam 16 combination product: Telazol. 17 Some trade or other names for Tiletamine: 18 2-(ethylamino)-2-(2-thienyl)-cyclohexanone. 19 Some trade or other names for zolazepam: 20 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo- 21 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon. 22 (11) Any material, compound, mixture or preparation 23 containing not more than 12.5 milligrams of pentazocine or 24 any of its salts, per 325 milligrams of aspirin; 25 (12) Any material, compound, mixture or preparation 26 containing not more than 12.5 milligrams of pentazocine or HB2534 Engrossed - 35 - LRB100 08419 RLC 18533 b

1 any of its salts, per 325 milligrams of acetaminophen; 2 (13) Any material, compound, mixture or preparation 3 containing not more than 50 milligrams of pentazocine or 4 any of its salts plus naloxone HCl USP 0.5 milligrams, per 5 dosage unit; 6 (14) ; 7 (15) Thiopental. 8 (d) . 9 (d.5) . 10 (e) Unless specifically excepted or unless listed in 11 another schedule, any material, compound, mixture, or 12 preparation containing limited quantities of any of the 13 following narcotic drugs, or their salts calculated as the free 14 anhydrous base or alkaloid, as set forth below: 15 (1) not more than 1.8 grams of codeine per 100 16 milliliters or not more than 90 milligrams per dosage unit, 17 with an equal or greater quantity of an isoquinoline 18 alkaloid of opium; 19 (2) not more than 1.8 grams of codeine per 100 20 milliliters or not more than 90 milligrams per dosage unit, 21 with one or more active non-narcotic ingredients in 22 recognized therapeutic amounts; 23 (3) (blank); not more than 300 milligrams of 24 dihydrocodeinone per 100 milliliters or not more than 15 25 milligrams per dosage unit, with a fourfold or greater 26 quantity of an isoquinoline alkaloid of opium; HB2534 Engrossed - 36 - LRB100 08419 RLC 18533 b

1 (4) (blank); not more than 300 milligrams of 2 dihydrocodeinone per 100 milliliters or not more than 15 3 milligrams per dosage unit, with one or more active, 4 non-narcotic ingredients in recognized therapeutic 5 amounts; 6 (5) not more than 1.8 grams of dihydrocodeine per 100 7 milliliters or not more than 90 milligrams per dosage unit, 8 with one or more active, non-narcotic ingredients in 9 recognized therapeutic amounts; 10 (6) not more than 300 milligrams of ethylmorphine per 11 100 milliliters or not more than 15 milligrams per dosage 12 unit, with one or more active, non-narcotic ingredients in 13 recognized therapeutic amounts; 14 (7) not more than 500 milligrams of opium per 100 15 milliliters or per 100 grams, or not more than 25 16 milligrams per dosage unit, with one or more active, 17 non-narcotic ingredients in recognized therapeutic 18 amounts; 19 (8) not more than 50 milligrams of morphine per 100 20 milliliters or per 100 grams with one or more active, 21 non-narcotic ingredients in recognized therapeutic 22 amounts. 23 (f) Anabolic steroids, except the following anabolic 24 steroids that are exempt: 25 (1) Androgyn L.A.; 26 (2) Andro-Estro 90-4; HB2534 Engrossed - 37 - LRB100 08419 RLC 18533 b

1 (3) depANDROGYN; 2 (4) DEPO-T.E.; 3 (5) depTESTROGEN; 4 (6) Duomone; 5 (7) DURATESTRIN; 6 (8) DUO-SPAN II; 7 (9) Estratest; 8 (10) Estratest H.S.; 9 (11) PAN ESTRA TEST; 10 (12) Premarin with Methyltestosterone; 11 (13) TEST-ESTRO Cypionates; 12 (14) Testosterone Cyp 50 Estradiol Cyp 2; 13 (15) Testosterone Cypionate-Estradiol Cypionate 14 injection; and 15 (16) Testosterone Enanthate-Estradiol Valerate 16 injection. 17 (g) Hallucinogenic substances. 18 (1) Dronabinol (synthetic) in sesame oil and 19 encapsulated in a soft gelatin capsule in a U.S. Food and 20 Drug Administration approved product. Some other names for 21 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- 22 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or 23 (-)-delta-9-(trans)-. 24 (2) (Reserved). 25 (h) The Department may except by rule any compound, 26 mixture, or preparation containing any stimulant or depressant HB2534 Engrossed - 38 - LRB100 08419 RLC 18533 b

1 substance listed in subsection (b) from the application of all 2 or any part of this Act if the compound, mixture, or 3 preparation contains one or more active medicinal ingredients 4 not having a stimulant or depressant effect on the central 5 nervous system, and if the admixtures are included therein in 6 combinations, quantity, proportion, or concentration that 7 vitiate the potential for abuse of the substances which have a 8 stimulant or depressant effect on the central nervous system. 9 (Source: P.A. 96-328, eff. 8-11-09; 96-1000, eff. 7-2-10; 10 97-334, eff. 1-1-12.)

11 (720 ILCS 570/401) (from Ch. 56 1/2, par. 1401) 12 Sec. 401. Manufacture or delivery, or possession with 13 intent to manufacture or deliver, a controlled substance, a 14 counterfeit substance, or controlled substance analog. Except 15 as authorized by this Act, it is unlawful for any person 16 knowingly to manufacture or deliver, or possess with intent to 17 manufacture or deliver, a controlled substance other than 18 methamphetamine and other than as defined in the 19 Bath Salts Prohibition Act sold or offered for sale in a retail 20 mercantile establishment as defined in Section 16-0.1 of the 21 Criminal Code of 2012, a counterfeit substance, or a controlled 22 substance analog. A violation of this Act with respect to each 23 of the controlled substances listed herein constitutes a single 24 and separate violation of this Act. For purposes of this 25 Section, "controlled substance analog" or "analog" means a HB2534 Engrossed - 39 - LRB100 08419 RLC 18533 b

1 substance, other than a controlled substance, which is not 2 approved by the United States Food and Drug Administration or, 3 if approved, is not dispensed or possessed in accordance with 4 State or federal law, and that has a chemical structure 5 substantially similar to that of a controlled substance in 6 Schedule I or II, or that was specifically designed to produce 7 an effect substantially similar to that of a controlled 8 substance in Schedule I or II. Examples of chemical classes in 9 which controlled substance analogs are found include, but are 10 not limited to, the following: , N-substituted 11 , , ecgonines, quinazolinones, 12 substituted indoles, and arylcycloalkylamines. For purposes of 13 this Act, a controlled substance analog shall be treated in the 14 same manner as the controlled substance to which it is 15 substantially similar. 16 (a) Any person who violates this Section with respect to 17 the following amounts of controlled or counterfeit substances 18 or controlled substance analogs, notwithstanding any of the 19 provisions of subsections (c), (d), (e), (f), (g) or (h) to the 20 contrary, is guilty of a Class X felony and shall be sentenced 21 to a term of imprisonment as provided in this subsection (a) 22 and fined as provided in subsection (b): 23 (1) (A) not less than 6 years and not more than 30 24 years with respect to 15 grams or more but less than 25 100 grams of a substance containing heroin, or an 26 analog thereof; HB2534 Engrossed - 40 - LRB100 08419 RLC 18533 b

1 (B) not less than 9 years and not more than 40 2 years with respect to 100 grams or more but less than 3 400 grams of a substance containing heroin, or an 4 analog thereof; 5 (C) not less than 12 years and not more than 50 6 years with respect to 400 grams or more but less than 7 900 grams of a substance containing heroin, or an 8 analog thereof; 9 (D) not less than 15 years and not more than 60 10 years with respect to 900 grams or more of any 11 substance containing heroin, or an analog thereof; 12 (1.5) (A) not less than 6 years and not more than 30 13 years with respect to 15 grams or more but less than 14 100 grams of a substance containing fentanyl, or an 15 analog thereof; 16 (B) not less than 9 years and not more than 40 17 years with respect to 100 grams or more but less than 18 400 grams of a substance containing fentanyl, or an 19 analog thereof; 20 (C) not less than 12 years and not more than 50 21 years with respect to 400 grams or more but less than 22 900 grams of a substance containing fentanyl, or an 23 analog thereof; 24 (D) not less than 15 years and not more than 60 25 years with respect to 900 grams or more of a substance 26 containing fentanyl, or an analog thereof; HB2534 Engrossed - 41 - LRB100 08419 RLC 18533 b

1 (2) (A) not less than 6 years and not more than 30 2 years with respect to 15 grams or more but less than 3 100 grams of a substance containing cocaine, or an 4 analog thereof; 5 (B) not less than 9 years and not more than 40 6 years with respect to 100 grams or more but less than 7 400 grams of a substance containing cocaine, or an 8 analog thereof; 9 (C) not less than 12 years and not more than 50 10 years with respect to 400 grams or more but less than 11 900 grams of a substance containing cocaine, or an 12 analog thereof; 13 (D) not less than 15 years and not more than 60 14 years with respect to 900 grams or more of any 15 substance containing cocaine, or an analog thereof; 16 (3) (A) not less than 6 years and not more than 30 17 years with respect to 15 grams or more but less than 18 100 grams of a substance containing morphine, or an 19 analog thereof; 20 (B) not less than 9 years and not more than 40 21 years with respect to 100 grams or more but less than 22 400 grams of a substance containing morphine, or an 23 analog thereof; 24 (C) not less than 12 years and not more than 50 25 years with respect to 400 grams or more but less than 26 900 grams of a substance containing morphine, or an HB2534 Engrossed - 42 - LRB100 08419 RLC 18533 b

1 analog thereof; 2 (D) not less than 15 years and not more than 60 3 years with respect to 900 grams or more of a substance 4 containing morphine, or an analog thereof; 5 (4) 200 grams or more of any substance containing 6 peyote, or an analog thereof; 7 (5) 200 grams or more of any substance containing a 8 derivative of barbituric acid or any of the salts of a 9 derivative of barbituric acid, or an analog thereof; 10 (6) 200 grams or more of any substance containing 11 amphetamine or any salt of an optical isomer of 12 amphetamine, or an analog thereof; 13 (6.5) (blank); 14 (6.6) (blank); 15 (7) (A) not less than 6 years and not more than 30 16 years with respect to: (i) 15 grams or more but less 17 than 100 grams of a substance containing lysergic acid 18 diethylamide (LSD), or an analog thereof, or (ii) 15 or 19 more objects or 15 or more segregated parts of an 20 object or objects but less than 200 objects or 200 21 segregated parts of an object or objects containing in 22 them or having upon them any amounts of any substance 23 containing lysergic acid diethylamide (LSD), or an 24 analog thereof; 25 (B) not less than 9 years and not more than 40 26 years with respect to: (i) 100 grams or more but less HB2534 Engrossed - 43 - LRB100 08419 RLC 18533 b

1 than 400 grams of a substance containing lysergic acid 2 diethylamide (LSD), or an analog thereof, or (ii) 200 3 or more objects or 200 or more segregated parts of an 4 object or objects but less than 600 objects or less 5 than 600 segregated parts of an object or objects 6 containing in them or having upon them any amount of 7 any substance containing lysergic acid diethylamide 8 (LSD), or an analog thereof; 9 (C) not less than 12 years and not more than 50 10 years with respect to: (i) 400 grams or more but less 11 than 900 grams of a substance containing lysergic acid 12 diethylamide (LSD), or an analog thereof, or (ii) 600 13 or more objects or 600 or more segregated parts of an 14 object or objects but less than 1500 objects or 1500 15 segregated parts of an object or objects containing in 16 them or having upon them any amount of any substance 17 containing lysergic acid diethylamide (LSD), or an 18 analog thereof; 19 (D) not less than 15 years and not more than 60 20 years with respect to: (i) 900 grams or more of any 21 substance containing lysergic acid diethylamide (LSD), 22 or an analog thereof, or (ii) 1500 or more objects or 23 1500 or more segregated parts of an object or objects 24 containing in them or having upon them any amount of a 25 substance containing lysergic acid diethylamide (LSD), 26 or an analog thereof; HB2534 Engrossed - 44 - LRB100 08419 RLC 18533 b

1 (7.5) (A) not less than 6 years and not more than 30 2 years with respect to: (i) 15 grams or more but less 3 than 100 grams of a substance listed in paragraph (1), 4 (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), 5 (21), (25), or (26) of subsection (d) of Section 204, 6 or an analog or derivative thereof, or (ii) 15 or more 7 pills, tablets, caplets, capsules, or objects but less 8 than 200 pills, tablets, caplets, capsules, or objects 9 containing in them or having upon them any amounts of 10 any substance listed in paragraph (1), (2), (2.1), 11 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or 12 (26) of subsection (d) of Section 204, or an analog or 13 derivative thereof; 14 (B) not less than 9 years and not more than 40 15 years with respect to: (i) 100 grams or more but less 16 than 400 grams of a substance listed in paragraph (1), 17 (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), 18 (21), (25), or (26) of subsection (d) of Section 204, 19 or an analog or derivative thereof, or (ii) 200 or more 20 pills, tablets, caplets, capsules, or objects but less 21 than 600 pills, tablets, caplets, capsules, or objects 22 containing in them or having upon them any amount of 23 any substance listed in paragraph (1), (2), (2.1), 24 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or 25 (26) of subsection (d) of Section 204, or an analog or 26 derivative thereof; HB2534 Engrossed - 45 - LRB100 08419 RLC 18533 b

1 (C) not less than 12 years and not more than 50 2 years with respect to: (i) 400 grams or more but less 3 than 900 grams of a substance listed in paragraph (1), 4 (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), 5 (21), (25), or (26) of subsection (d) of Section 204, 6 or an analog or derivative thereof, or (ii) 600 or more 7 pills, tablets, caplets, capsules, or objects but less 8 than 1,500 pills, tablets, caplets, capsules, or 9 objects containing in them or having upon them any 10 amount of any substance listed in paragraph (1), (2), 11 (2.1), (2.2), (3), (14.1), (19), (20), (20.1), (21), 12 (25), or (26) of subsection (d) of Section 204, or an 13 analog or derivative thereof; 14 (D) not less than 15 years and not more than 60 15 years with respect to: (i) 900 grams or more of any 16 substance listed in paragraph (1), (2), (2.1), (2.2), 17 (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of 18 subsection (d) of Section 204, or an analog or 19 derivative thereof, or (ii) 1,500 or more pills, 20 tablets, caplets, capsules, or objects containing in 21 them or having upon them any amount of a substance 22 listed in paragraph (1), (2), (2.1), (2.2), (3), 23 (14.1), (19), (20), (20.1), (21), (25), or (26) of 24 subsection (d) of Section 204, or an analog or 25 derivative thereof; 26 (8) 30 grams or more of any substance containing HB2534 Engrossed - 46 - LRB100 08419 RLC 18533 b

1 pentazocine or any of the salts, isomers and salts of 2 isomers of pentazocine, or an analog thereof; 3 (9) 30 grams or more of any substance containing 4 methaqualone or any of the salts, isomers and salts of 5 isomers of methaqualone, or an analog thereof; 6 (10) 30 grams or more of any substance containing 7 phencyclidine or any of the salts, isomers and salts of 8 isomers of phencyclidine (PCP), or an analog thereof; 9 (10.5) 30 grams or more of any substance containing 10 ketamine or any of the salts, isomers and salts of isomers 11 of ketamine, or an analog thereof; 12 (10.6) 100 grams or more of any substance containing 13 hydrocodone, or any of the salts, isomers and salts of 14 isomers of hydrocodone, or an analog thereof; 15 (10.7) (blank); 100 grams or more of any substance 16 containing dihydrocodeinone, or any of the salts, isomers 17 and salts of isomers of dihydrocodeinone, or an analog 18 thereof; 19 (10.8) 100 grams or more of any substance containing 20 dihydrocodeine, or any of the salts, isomers and salts of 21 isomers of dihydrocodeine, or an analog thereof; 22 (10.9) 100 grams or more of any substance containing 23 oxycodone, or any of the salts, isomers and salts of 24 isomers of oxycodone, or an analog thereof; 25 (11) 200 grams or more of any substance containing any 26 other controlled substance classified in Schedules I or II, HB2534 Engrossed - 47 - LRB100 08419 RLC 18533 b

1 or an analog thereof, which is not otherwise included in 2 this subsection. 3 (b) Any person sentenced with respect to violations of 4 paragraph (1), (2), (3), (7), or (7.5) of subsection (a) 5 involving 100 grams or more of the controlled substance named 6 therein, may in addition to the penalties provided therein, be 7 fined an amount not more than $500,000 or the full street value 8 of the controlled or counterfeit substance or controlled 9 substance analog, whichever is greater. The term "street value" 10 shall have the meaning ascribed in Section 110-5 of the Code of 11 Criminal Procedure of 1963. Any person sentenced with respect 12 to any other provision of subsection (a), may in addition to 13 the penalties provided therein, be fined an amount not to 14 exceed $500,000. 15 (b-1) Excluding violations of this Act when the controlled 16 substance is fentanyl, any person sentenced to a term of 17 imprisonment with respect to violations of Section 401, 401.1, 18 405, 405.1, 405.2, or 407, when the substance containing the 19 controlled substance contains any amount of fentanyl, 3 years 20 shall be added to the term of imprisonment imposed by the 21 court, and the maximum sentence for the offense shall be 22 increased by 3 years. 23 (c) Any person who violates this Section with regard to the 24 following amounts of controlled or counterfeit substances or 25 controlled substance analogs, notwithstanding any of the 26 provisions of subsections (a), (b), (d), (e), (f), (g) or (h) HB2534 Engrossed - 48 - LRB100 08419 RLC 18533 b

1 to the contrary, is guilty of a Class 1 felony. The fine for 2 violation of this subsection (c) shall not be more than 3 $250,000: 4 (1) 1 gram or more but less than 15 grams of any 5 substance containing heroin, or an analog thereof; 6 (1.5) 1 gram or more but less than 15 grams of any 7 substance containing fentanyl, or an analog thereof; 8 (2) 1 gram or more but less than 15 grams of any 9 substance containing cocaine, or an analog thereof; 10 (3) 10 grams or more but less than 15 grams of any 11 substance containing morphine, or an analog thereof; 12 (4) 50 grams or more but less than 200 grams of any 13 substance containing peyote, or an analog thereof; 14 (5) 50 grams or more but less than 200 grams of any 15 substance containing a derivative of barbituric acid or any 16 of the salts of a derivative of barbituric acid, or an 17 analog thereof; 18 (6) 50 grams or more but less than 200 grams of any 19 substance containing amphetamine or any salt of an optical 20 isomer of amphetamine, or an analog thereof; 21 (6.5) (blank); 22 (7) (i) 5 grams or more but less than 15 grams of any 23 substance containing lysergic acid diethylamide (LSD), or 24 an analog thereof, or (ii) more than 10 objects or more 25 than 10 segregated parts of an object or objects but less 26 than 15 objects or less than 15 segregated parts of an HB2534 Engrossed - 49 - LRB100 08419 RLC 18533 b

1 object containing in them or having upon them any amount of 2 any substance containing lysergic acid diethylamide (LSD), 3 or an analog thereof; 4 (7.5) (i) 5 grams or more but less than 15 grams of any 5 substance listed in paragraph (1), (2), (2.1), (2.2), (3), 6 (14.1), (19), (20), (20.1), (21), (25), or (26) of 7 subsection (d) of Section 204, or an analog or derivative 8 thereof, or (ii) more than 10 pills, tablets, caplets, 9 capsules, or objects but less than 15 pills, tablets, 10 caplets, capsules, or objects containing in them or having 11 upon them any amount of any substance listed in paragraph 12 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), 13 (21), (25), or (26) of subsection (d) of Section 204, or an 14 analog or derivative thereof; 15 (8) 10 grams or more but less than 30 grams of any 16 substance containing pentazocine or any of the salts, 17 isomers and salts of isomers of pentazocine, or an analog 18 thereof; 19 (9) 10 grams or more but less than 30 grams of any 20 substance containing methaqualone or any of the salts, 21 isomers and salts of isomers of methaqualone, or an analog 22 thereof; 23 (10) 10 grams or more but less than 30 grams of any 24 substance containing phencyclidine or any of the salts, 25 isomers and salts of isomers of phencyclidine (PCP), or an 26 analog thereof; HB2534 Engrossed - 50 - LRB100 08419 RLC 18533 b

1 (10.5) 10 grams or more but less than 30 grams of any 2 substance containing ketamine or any of the salts, isomers 3 and salts of isomers of ketamine, or an analog thereof; 4 (10.6) 50 grams or more but less than 100 grams of any 5 substance containing hydrocodone, or any of the salts, 6 isomers and salts of isomers of hydrocodone, or an analog 7 thereof; 8 (10.7) (blank); 50 grams or more but less than 100 9 grams of any substance containing dihydrocodeinone, or any 10 of the salts, isomers and salts of isomers of 11 dihydrocodeinone, or an analog thereof; 12 (10.8) 50 grams or more but less than 100 grams of any 13 substance containing dihydrocodeine, or any of the salts, 14 isomers and salts of isomers of dihydrocodeine, or an 15 analog thereof; 16 (10.9) 50 grams or more but less than 100 grams of any 17 substance containing oxycodone, or any of the salts, 18 isomers and salts of isomers of oxycodone, or an analog 19 thereof; 20 (11) 50 grams or more but less than 200 grams of any 21 substance containing a substance classified in Schedules I 22 or II, or an analog thereof, which is not otherwise 23 included in this subsection. 24 (c-5) (Blank). 25 (d) Any person who violates this Section with regard to any 26 other amount of a controlled or counterfeit substance HB2534 Engrossed - 51 - LRB100 08419 RLC 18533 b

1 containing dihydrocodeinone or dihydrocodeine or classified in 2 Schedules I or II, or an analog thereof, which is (i) a 3 narcotic drug, (ii) lysergic acid diethylamide (LSD) or an 4 analog thereof, (iii) any substance containing amphetamine or 5 fentanyl or any salt or optical isomer of amphetamine or 6 fentanyl, or an analog thereof, or (iv) any substance 7 containing N-Benzylpiperazine (BZP) or any salt or optical 8 isomer of N-Benzylpiperazine (BZP), or an analog thereof, is 9 guilty of a Class 2 felony. The fine for violation of this 10 subsection (d) shall not be more than $200,000. 11 (d-5) (Blank). 12 (e) Any person who violates this Section with regard to any 13 other amount of a controlled substance other than 14 methamphetamine or counterfeit substance classified in 15 Schedule I or II, or an analog thereof, which substance is not 16 included under subsection (d) of this Section, is guilty of a 17 Class 3 felony. The fine for violation of this subsection (e) 18 shall not be more than $150,000. 19 (f) Any person who violates this Section with regard to any 20 other amount of a controlled or counterfeit substance 21 classified in Schedule III is guilty of a Class 3 felony. The 22 fine for violation of this subsection (f) shall not be more 23 than $125,000. 24 (g) Any person who violates this Section with regard to any 25 other amount of a controlled or counterfeit substance 26 classified in Schedule IV is guilty of a Class 3 felony. The HB2534 Engrossed - 52 - LRB100 08419 RLC 18533 b

1 fine for violation of this subsection (g) shall not be more 2 than $100,000. 3 (h) Any person who violates this Section with regard to any 4 other amount of a controlled or counterfeit substance 5 classified in Schedule V is guilty of a Class 3 felony. The 6 fine for violation of this subsection (h) shall not be more 7 than $75,000. 8 (i) This Section does not apply to the manufacture, 9 possession or distribution of a substance in conformance with 10 the provisions of an approved new drug application or an 11 exemption for investigational use within the meaning of Section 12 505 of the Federal Food, Drug and Cosmetic Act. 13 (j) (Blank). 14 (Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17.)

15 (720 ILCS 570/402) (from Ch. 56 1/2, par. 1402) 16 Sec. 402. Except as otherwise authorized by this Act, it is 17 unlawful for any person knowingly to possess a controlled or 18 counterfeit substance or controlled substance analog. A 19 violation of this Act with respect to each of the controlled 20 substances listed herein constitutes a single and separate 21 violation of this Act. For purposes of this Section, 22 "controlled substance analog" or "analog" means a substance, 23 other than a controlled substance, which is not approved by the 24 United States Food and Drug Administration or, if approved, is 25 not dispensed or possessed in accordance with State or federal HB2534 Engrossed - 53 - LRB100 08419 RLC 18533 b

1 law, and that has a chemical structure substantially similar to 2 that of a controlled substance in Schedule I or II, or that was 3 specifically designed to produce an effect substantially 4 similar to that of a controlled substance in Schedule I or II. 5 Examples of chemical classes in which controlled substance 6 analogs are found include, but are not limited to, the 7 following: phenethylamines, N-substituted piperidines, 8 morphinans, ecgonines, quinazolinones, substituted indoles, 9 and arylcycloalkylamines. For purposes of this Act, a 10 controlled substance analog shall be treated in the same manner 11 as the controlled substance to which it is substantially 12 similar. 13 (a) Any person who violates this Section with respect to 14 the following controlled or counterfeit substances and 15 amounts, notwithstanding any of the provisions of subsections 16 (c) and (d) to the contrary, is guilty of a Class 1 felony and 17 shall, if sentenced to a term of imprisonment, be sentenced as 18 provided in this subsection (a) and fined as provided in 19 subsection (b): 20 (1) (A) not less than 4 years and not more than 15 21 years with respect to 15 grams or more but less than 22 100 grams of a substance containing heroin; 23 (B) not less than 6 years and not more than 30 24 years with respect to 100 grams or more but less than 25 400 grams of a substance containing heroin; 26 (C) not less than 8 years and not more than 40 HB2534 Engrossed - 54 - LRB100 08419 RLC 18533 b

1 years with respect to 400 grams or more but less than 2 900 grams of any substance containing heroin; 3 (D) not less than 10 years and not more than 50 4 years with respect to 900 grams or more of any 5 substance containing heroin; 6 (2) (A) not less than 4 years and not more than 15 7 years with respect to 15 grams or more but less than 8 100 grams of any substance containing cocaine; 9 (B) not less than 6 years and not more than 30 10 years with respect to 100 grams or more but less than 11 400 grams of any substance containing cocaine; 12 (C) not less than 8 years and not more than 40 13 years with respect to 400 grams or more but less than 14 900 grams of any substance containing cocaine; 15 (D) not less than 10 years and not more than 50 16 years with respect to 900 grams or more of any 17 substance containing cocaine; 18 (3) (A) not less than 4 years and not more than 15 19 years with respect to 15 grams or more but less than 20 100 grams of any substance containing morphine; 21 (B) not less than 6 years and not more than 30 22 years with respect to 100 grams or more but less than 23 400 grams of any substance containing morphine; 24 (C) not less than 6 years and not more than 40 25 years with respect to 400 grams or more but less than 26 900 grams of any substance containing morphine; HB2534 Engrossed - 55 - LRB100 08419 RLC 18533 b

1 (D) not less than 10 years and not more than 50 2 years with respect to 900 grams or more of any 3 substance containing morphine; 4 (4) 200 grams or more of any substance containing 5 peyote; 6 (5) 200 grams or more of any substance containing a 7 derivative of barbituric acid or any of the salts of a 8 derivative of barbituric acid; 9 (6) 200 grams or more of any substance containing 10 amphetamine or any salt of an optical isomer of 11 amphetamine; 12 (6.5) (blank); 13 (7) (A) not less than 4 years and not more than 15 14 years with respect to: (i) 15 grams or more but less 15 than 100 grams of any substance containing lysergic 16 acid diethylamide (LSD), or an analog thereof, or (ii) 17 15 or more objects or 15 or more segregated parts of an 18 object or objects but less than 200 objects or 200 19 segregated parts of an object or objects containing in 20 them or having upon them any amount of any substance 21 containing lysergic acid diethylamide (LSD), or an 22 analog thereof; 23 (B) not less than 6 years and not more than 30 24 years with respect to: (i) 100 grams or more but less 25 than 400 grams of any substance containing lysergic 26 acid diethylamide (LSD), or an analog thereof, or (ii) HB2534 Engrossed - 56 - LRB100 08419 RLC 18533 b

1 200 or more objects or 200 or more segregated parts of 2 an object or objects but less than 600 objects or less 3 than 600 segregated parts of an object or objects 4 containing in them or having upon them any amount of 5 any substance containing lysergic acid diethylamide 6 (LSD), or an analog thereof; 7 (C) not less than 8 years and not more than 40 8 years with respect to: (i) 400 grams or more but less 9 than 900 grams of any substance containing lysergic 10 acid diethylamide (LSD), or an analog thereof, or (ii) 11 600 or more objects or 600 or more segregated parts of 12 an object or objects but less than 1500 objects or 1500 13 segregated parts of an object or objects containing in 14 them or having upon them any amount of any substance 15 containing lysergic acid diethylamide (LSD), or an 16 analog thereof; 17 (D) not less than 10 years and not more than 50 18 years with respect to: (i) 900 grams or more of any 19 substance containing lysergic acid diethylamide (LSD), 20 or an analog thereof, or (ii) 1500 or more objects or 21 1500 or more segregated parts of an object or objects 22 containing in them or having upon them any amount of a 23 substance containing lysergic acid diethylamide (LSD), 24 or an analog thereof; 25 (7.5) (A) not less than 4 years and not more than 15 26 years with respect to: (i) 15 grams or more but less HB2534 Engrossed - 57 - LRB100 08419 RLC 18533 b

1 than 100 grams of any substance listed in paragraph 2 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), 3 (20.1), (21), (25), or (26) of subsection (d) of 4 Section 204, or an analog or derivative thereof, or 5 (ii) 15 or more pills, tablets, caplets, capsules, or 6 objects but less than 200 pills, tablets, caplets, 7 capsules, or objects containing in them or having upon 8 them any amount of any substance listed in paragraph 9 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), 10 (20.1), (21), (25), or (26) of subsection (d) of 11 Section 204, or an analog or derivative thereof; 12 (B) not less than 6 years and not more than 30 13 years with respect to: (i) 100 grams or more but less 14 than 400 grams of any substance listed in paragraph 15 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), 16 (20.1), (21), (25), or (26) of subsection (d) of 17 Section 204, or an analog or derivative thereof, or 18 (ii) 200 or more pills, tablets, caplets, capsules, or 19 objects but less than 600 pills, tablets, caplets, 20 capsules, or objects containing in them or having upon 21 them any amount of any substance listed in paragraph 22 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), 23 (20.1), (21), (25), or (26) of subsection (d) of 24 Section 204, or an analog or derivative thereof; 25 (C) not less than 8 years and not more than 40 26 years with respect to: (i) 400 grams or more but less HB2534 Engrossed - 58 - LRB100 08419 RLC 18533 b

1 than 900 grams of any substance listed in paragraph 2 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), 3 (20.1), (21), (25), or (26) of subsection (d) of 4 Section 204, or an analog or derivative thereof, or 5 (ii) 600 or more pills, tablets, caplets, capsules, or 6 objects but less than 1,500 pills, tablets, caplets, 7 capsules, or objects containing in them or having upon 8 them any amount of any substance listed in paragraph 9 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), 10 (20.1), (21), (25), or (26) of subsection (d) of 11 Section 204, or an analog or derivative thereof; 12 (D) not less than 10 years and not more than 50 13 years with respect to: (i) 900 grams or more of any 14 substance listed in paragraph (1), (2), (2.1), (2.2), 15 (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of 16 subsection (d) of Section 204, or an analog or 17 derivative thereof, or (ii) 1,500 or more pills, 18 tablets, caplets, capsules, or objects containing in 19 them or having upon them any amount of a substance 20 listed in paragraph (1), (2), (2.1), (2.2), (3), 21 (14.1), (19), (20), (20.1), (21), (25), or (26) of 22 subsection (d) of Section 204, or an analog or 23 derivative thereof; 24 (8) 30 grams or more of any substance containing 25 pentazocine or any of the salts, isomers and salts of 26 isomers of pentazocine, or an analog thereof; HB2534 Engrossed - 59 - LRB100 08419 RLC 18533 b

1 (9) 30 grams or more of any substance containing 2 methaqualone or any of the salts, isomers and salts of 3 isomers of methaqualone; 4 (10) 30 grams or more of any substance containing 5 phencyclidine or any of the salts, isomers and salts of 6 isomers of phencyclidine (PCP); 7 (10.5) 30 grams or more of any substance containing 8 ketamine or any of the salts, isomers and salts of isomers 9 of ketamine; 10 (11) 200 grams or more of any substance containing any 11 substance classified as a narcotic drug in Schedules I or 12 II, or an analog thereof, which is not otherwise included 13 in this subsection. 14 (b) Any person sentenced with respect to violations of 15 paragraph (1), (2), (3), (7), or (7.5) of subsection (a) 16 involving 100 grams or more of the controlled substance named 17 therein, may in addition to the penalties provided therein, be 18 fined an amount not to exceed $200,000 or the full street value 19 of the controlled or counterfeit substances, whichever is 20 greater. The term "street value" shall have the meaning 21 ascribed in Section 110-5 of the Code of Criminal Procedure of 22 1963. Any person sentenced with respect to any other provision 23 of subsection (a), may in addition to the penalties provided 24 therein, be fined an amount not to exceed $200,000. 25 (c) Any person who violates this Section with regard to an 26 amount of a controlled substance other than methamphetamine or HB2534 Engrossed - 60 - LRB100 08419 RLC 18533 b

1 counterfeit substance not set forth in subsection (a) or (d) is 2 guilty of a Class 4 felony. The fine for a violation punishable 3 under this subsection (c) shall not be more than $25,000. 4 (d) Any person who violates this Section with regard to any 5 amount of anabolic steroid is guilty of a Class C misdemeanor 6 for the first offense and a Class B misdemeanor for a 7 subsequent offense committed within 2 years of a prior 8 conviction. 9 (Source: P.A. 99-371, eff. 1-1-16.)